Pro-Inflammatory cytokines & neurobehavioral symptoms in breast cancer patients

促炎细胞因子

• 批准号: 7740298
• 负责人: Sunita K Patel
• 金额: $ 18.26万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7740298
• 关键词: Acute; Address; Aftercare; Behavioral; Behavioral Symptoms; Benign; Biological Markers; Breast; Breast Carcinoma; Cancer Patient; Chronic; Clinical; Cognitive; Cross-Sectional Studies; Cytokine Network Pathway; Diagnosis; Diagnostic Neoplasm Staging; Disease; Employee Strikes; Evaluation; Fatigue; Functional disorder; Goals; Immunologics; Impaired cognition; Individual; Inflammatory; Interleukin-1; Interleukin-6; Knowledge; Late Effects; Link; Literature; Local Therapy; Long-Term Survivors; Longitudinal Studies; Malignant Neoplasms; Measures; Methods; Neuraxis; Neurocognitive; Outcome; Participant; Patients; Plasma; Postmenopause; Prevalence; Proliferating; Relative (related person); Reporting; Research; Risk; Serum; Stage at Diagnosis; Survivors; Symptoms; TNF gene; Time; Woman; Women' s Group; Work; abstracting; anakinra; cancer cell; cancer therapy; chemotherapy; cognitive function; comparison group; cytokine; disease characteristic; disturbance in affect; experience; improved; malignant breast neoplasm; neurobehavioral; patient population; prognostic; public health relevance; receptor; response; survivorship; tumor

DESCRIPTION (provided by applicant): Pro-inflammatory cytokines and neurobehavioral symptoms in women with breast cancer. Abstract Survivors of breast cancer report debilitating behavioral symptoms, such as fatigue and neurocognitive dysfunction, which are evident in some individuals even at pre-treatment baseline. There is sufficient evidence from varied lines of research to propose that cancer-related neurobehavioral symptoms may be driven, at least in part, by activation of the pro-inflammatory cytokine network. Concentrations of specific pro-inflammatory cytokines (IL-6, TNF) and soluble receptors in serum obtained prior to treatment in breast cancer patients are significantly higher than levels found in healthy individuals and have prognostic value; however, these pre- treatment elevations have not yet been evaluated with respect to their association with either acute or chronic behavioral symptoms. Among survivors of breast cancer, elevated levels of circulating sIL-6R and IL-1ra have emerged as prominent biomarkers of persistent fatigue in cross-sectional studies of women several years post chemotherapy. No similar work has identified biomarkers of neurocognitive dysfunction in this patient population, and it is not known if the cytokine links with fatigue, or other behavioral symptoms, exist closer to the diagnosis period or evolve over time as "late effects". In this study, we will address this knowledge gap as we will evaluate this association prior to cancer treatment, and again following treatment completion. We will compare these associations in a minimum of 137 breast cancer patients relative to two comparison groups at pre-treatment, and longitudinally evaluate only the breast cancer group after treatment. Findings are expected to increase our knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects. PUBLIC HEALTH RELEVANCE: Findings are expected to increase knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects.

描述（由申请人提供）：乳腺癌女性的促炎细胞因子和神经行为症状。摘要 乳腺癌幸存者报告了令人衰弱的行为症状，例如疲劳和神经认知功能障碍，这些症状在某些个体中甚至在治疗前基线时就很明显。各种研究都有足够的证据表明，癌症相关的神经行为症状可能至少部分是由促炎细胞因子网络的激活驱动的。乳腺癌患者治疗前血清中特定促炎细胞因子（IL-6、TNF）和可溶性受体的浓度显着高于健康个体中的水平，具有预后价值；然而，尚未评估这些治疗前升高与急性或慢性行为症状的关联。在乳腺癌幸存者中，在化疗后数年的女性横断面研究中，循环 sIL-6R 和 IL-1ra 水平升高已成为持续性疲劳的重要生物标志物。目前还没有类似的工作在该患者群体中鉴定出神经认知功能障碍的生物标志物，并且尚不清楚细胞因子是否与疲劳或其他行为症状有关，是否在接近诊断期间存在或随着时间的推移而演变为“晚期效应”。在本研究中，我们将解决这一知识差距，因为我们将在癌症治疗之前以及治疗完成后再次评估这种关联。我们将在治疗前将至少 137 名乳腺癌患者与两个对照组的这些关联进行比较，并在治疗后仅纵向评估乳腺癌组。研究结果有望增加我们对与乳腺癌患者神经行为症状相关的可能生物标志物的了解，以便更好地识别和治疗有此类影响风险的患者。公共卫生相关性：研究结果预计将增加对与乳腺癌患者神经行为症状相关的可能生物标志物的了解，以便更好地识别和治疗有此类影响风险的患者。